Pulmonary arterial hypertension

About Us

Bharti Rana Jayshankar – Founder

She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.

Jay Shankar – Co-founder

He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.

Contact Info

info@healthquill.com

Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by the FDA.

Merck gets priority review nod from USFDA for hypertension drug

HQ Team September 28, 2023: Merck’s Biological Licence Application for a pulmonary arterial hypertension drug has been accepted for a priority review by.

by HealthQuill
September 28, 2023
0 Comments

Merck announced its experimental trial on patients with pulmonary arterial hypertension had led to an extension in walking distance and reduced exacerbating the condition by 84%.

Drugs Medical Pharma

Merck says trial hypertension drug enhances patients’ walk time

Merck announced its experimental trial on patients with pulmonary arterial hypertension had led to an extension in walking distance and reduced exacerbating the.

by HealthQuill
March 7, 2023
0 Comments

About Us

Contact Info

Follow Us

Merck gets priority review nod from USFDA for hypertension drug

Merck says trial hypertension drug enhances patients’ walk time￼

Merck says trial hypertension drug enhances patients’ walk time